NCT02876107

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Active, enrolled Phase 2 Last updated 15 April 2026

What this trial tests

Phase 2 trial testing Carboplatin in Breast Carcinoma in 42 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 October 2016

Primary endpoint
31 October 2027

31 October 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	6 October 2016
Primary completion	31 October 2027
Estimated completion	31 October 2027
Sites	1 location across United States

Drugs / interventions tested

• Carboplatin (Carboplatin) — full drug profile →
• Laboratory Biomarker Analysis — full drug profile →
• Paclitaxel — full drug profile →
• Panitumumab — full drug profile →

Conditions studied

• Breast Carcinoma — all drugs for Breast Carcinoma →
• Breast Lump — all drugs for Breast Lump →
• Edema — all drugs for Edema →
• Erythema — all drugs for Erythema →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Breast Carcinoma or Breast Lump. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized phase II trial studies how well carboplatin and paclitaxel with or without panitumumab work in treating patients with invasive triple negative breast cancer. Drugs used in the chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping the them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as panitumumab, may interfere with the ability of tumor cells to grow and spread. Giving carboplatin and paclitaxel with or without panitumumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Recent advances in therapeutic strategies for triple-negative breast cancer.
   Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
2. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
   Nedeljković M, Damjanović A. · · 2019 · cited 576× · PMID 31443516 · DOI 10.3390/cells8090957
3. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness.
   Lee KL, Kuo YC, Ho YS, Huang YH. · · 2019 · cited 164× · PMID 31505803 · DOI 10.3390/cancers11091334
4. Triple-negative breast cancer and the potential for targeted therapy.
   Jhan JR, Andrechek ER. · · 2017 · cited 155× · PMID 29095114 · DOI 10.2217/pgs-2017-0117
5. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
   Ferrari P, Scatena C, Ghilli M, Bargagna I, et al · · 2022 · cited 143× · PMID 35163586 · DOI 10.3390/ijms23031665
6. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
   Park JH, Ahn JH, Kim SB. · · 2018 · cited 109× · PMID 29765774 · DOI 10.1136/esmoopen-2018-000357
7. Immunotherapeutic interventions of Triple Negative Breast Cancer.
   Li Z, Qiu Y, Lu W, Jiang Y, et al · · 2018 · cited 99× · PMID 29848327 · DOI 10.1186/s12967-018-1514-7
8. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
   Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071